ClinicalTrials.gg
RecruitingNCT07338669HAKISUpdated Oct 1, 2026

Hamburg Acute Kidney Injury Study (HAKIS)

An observational study in Acute Kidney Injury and Acute Kidney Injury (AKI), sponsored by Universitätsklinikum Hamburg-Eppendorf. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Universitätsklinikum Hamburg-Eppendorf · Observational

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.
Updated Oct 1, 2026Eligibility revisedTitle changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 109 studies in Acute Kidney Injury with a site in Germany — 21 open to participants now, 24 under way, 1 of them phase 3. Acute Kidney Injury · Germany.

Planned enrollment
6th of 47
1,000 · median 120
Started
2025
with 7 others
Observational
47 of 109
7 open now
Primary completion
2026-09
later than 8 of 23 live
Registered
100th of 109
by date
Lead sponsor
4 of 109
Universitätsklinikum Hamburg-Eppendorf

Among the 109 studies in Acute Kidney Injury with a site in Germany, this one is the 6th largest by planned enrollment of the 47 observational ones that give a count, is one of 8 that started in 2025, is one of 47 observational ones, reaches primary completion later than 8 of the 23 other live ones, and was the 100th registered.

Acute Kidney Injury

1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

21 of the 109 studies in Acute Kidney Injury with a site in Germany are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 109 studies in Acute Kidney Injury with a site in Germany, or all of them as a file.
02

Study summary

The Hamburg Acute Kidney Injury Study (HAKIS) is a prospective observational cohort study aimed at investigating the mechanisms, risk factors, and clinical determinants of acute kidney injury (AKI) trajectories and consequences.

Read the detailed description

The Hamburg Acute Kidney Injury Study (HAKIS) is a prospective observational cohort study that includes hospitalized adults (≥18 years) at the time of acute kidney injury (AKI). Potential participants are identified during hospital care, and a structured IT-supported clinical screening system helps detect AKI cases in real time. In parallel, a control group of hospitalized adults with acute illness who have not developed AKI is enrolled to enable comparative analyses of specific risk factors, pathophysiology, and outcomes. All participants undergo a standardized clinical assessment of kidney function, comorbidities, hemodynamic status, medication exposure, procedures, and laboratory parameters. The study includes serial collection of clinical data and biosamples (blood and urine) at study inclusion, during hospitalization, and at 3-month after discharge. All biospecimens are processed within a harmonized pipeline and stored in the Hamburg and European Renal Omics-Biobank (HERO). Beyond the identification of clinical determinants of AKI trajectories, the central objective of HAKIS is to identify biological pathways of sustained kidney injury and repair, improve risk stratification, evaluated prognostic biomarkers, and support the development of precision medicine approaches in post AKI care. Long-term outcomes including progressive chronic kidney disease, cardiovascular events, hospital readmissions, and mortality are collected through annual structured follow-ups. No experimental interventions are performed and all clinical management follows standard of care.

03

Conditions studied

  • Acute Kidney Injury
  • Acute Kidney Injury (AKI)

Browse trials for

Keywords

  • Acute Kidney Injury
  • AKI
  • Prospective observational cohort study
04

Who can participate

The criteria were revised on the registry on Oct 1, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Hospitalized individuals with acute kidney injury (AKI) or at risk for AKI will be identified during routine medical care and invited for study participation. Routine clinical identification of AKI includes an IT-based screening system.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hospitalized individuals with acute kidney injury (AKI), defined by the 2012 Kidney Disease: Improving Global Outcomes (KDIGO) criteria or hospitalized individuals with acute illness who have not developed AKI (control group)
  • Age ≥ 18 years at time of enrollment
  • Written provided by the participant or, in participants lacking decision-making capacity, by a legal representative or healthcare proxy, where available. Participants lacking decision-making capacity without an available legal representative or healthcare proxy may be enrolled if participation is not contrary to their presumed wishes, in accordance with the ethics committee-approved consent procedure. Written informed consent is subsequently sought from the participant upon regaining decision-making capacity or from a legal representative, as applicable.

Exclusion criteria

Exclusion Criteria:

  • None
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • AKI group

    Group consists of adult hospitalized individuals, who meet the 2012 Kidney Disease: Improving Global Outcomes (KDIGO) criteria for acute kidney injury (AKI). Participants will be prospectively followed for clinical course, kidney function, biomarker analysis, and outcomes. No experimental interventions are performed. All care follows standard clinical practice.

  • Control group

    Group consists of adult hospitalized individuals with an acute illness, who have not developed acute kidney injury (AKI). Participants will be prospectively followed for clinical course, kidney function, biomarker analysis, and outcomes. No experimental interventions are performed. All care follows standard clinical practice.

06

What researchers measure

Primary outcomes

  1. Kidney Function Recovery after AKI

    Improvement of kidney function after acute kidney injury, defined by partial or complete return of the kidney function toward baseline values

    Time frame: assessed at discharge, 3-months after discharge, and annual follow-up

  2. Persistent Kidney Function Decline

    Sustained impairment of kidney function following acute kidney injury, characterized by incomplete recovery and persistently reduced kidney function over follow-up.

    Time frame: assessed at discharge, 3-months after discharge, and annual follow-up

  3. Development or Progression of Chronic Kidney Disease

    New onset or worsening of chronic kidney disease during follow-up, assessed based on changes in kidney function over time.

    Time frame: assessed at 3-months after discharge, and annual follow-up

  4. End-stage kidney disease (ESKD)

    Occurrence of ESKD, characterized by the initiation of maintenance kidney replacement therapy, kidney transplantation or a persistent eGFR \< 15 ml/min/1.73m2

    Time frame: assessed at discharge, 3-months after discharge, and annual follow-up

  5. Renal mortality

    Death attributable to kidney-related causes as determined by medical record review.

    Time frame: assessed at discharge, 3-months after discharge, and annual follow-up

  6. Cardiovascular Outcomes

    cardiovascular death, myocardial infarction, heart failure, arrhythmia, stroke

    Time frame: assessed at discharge, 3-months after discharge, and annual follow-up

Secondary outcomes

  1. Incidence of vascular diseases

    Occurrence of vascular disease, including coronary artery disease, peripheral artery disease, or cerebrovascular disease after AKI

    Time frame: assessed at discharge, 3 months after discharge, and annual follow-up

  2. Incidence of Dementia

    New diagnosis of dementia occurring during follow-up after AKI

    Time frame: assessed at discharge, 3 months after discharge, and annual follow-up

  3. Incidence of Cancer

    New diagnosis of malignant disease occurring during follow-up after AKI

    Time frame: assessed at discharge, 3 months after discharge, and annual follow-up

  4. Incidence of Infections

    New diagnosis of infections occurring during follow-up after AKI

    Time frame: assessed at discharge, 3 months after discharge, and annual follow-up

  5. Incidence of psychosomatic or Psychiatric Disorders

    New diagnosis of psychosomatic or psychiatric disorders occurring during follow-up after AKI

    Time frame: assessed at discharge, 3 months after discharge, and annual follow-up

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Sep 2026, 12 months after the start.

Of 350 non-industry observational studies under Acute Kidney Injury, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 12 months is below that.

Counting every sponsor, half of 365 studies reached it within 24 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2025
First posted
Jan 14, 2026
StartActual
Sep 16, 2025
Primary completionEst.
Sep 2026
CompletionEst.
Sep 2030
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 inclusion criterion added, 1 removed
What changed in the criteria
Inclusion criteria
  • RemovedPersonally signed informed consent
  • AddedWritten informed consent provided by the participant or, in participants lacking decision-making capacity, by a legal representative or healthcare proxy, where available. Participants lacking decision-making capacity without an available legal representative or healthcare proxy may be enrolled if participation is not contrary to their presumed wishes, in accordance with the ethics committee-approved consent procedure. Written informed consent is subsequently sought from the participant upon regaining decision-making capacity or from a legal representative, as applicable.
Oct 1, 2026
Title
Hamburg Acute RenalKidney Injury Study (HARISHAKIS)
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Eligibility 1 inclusion criterion added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedPersonally signed informed consent
    • AddedWritten informed consent provided by the participant or, in participants lacking decision-making capacity, by a legal representative or healthcare proxy, where available. Participants lacking decision-making capacity without an available legal representative or healthcare proxy may be enrolled if participation is not contrary to their presumed wishes, in accordance with the ethics committee-approved consent procedure. Written informed consent is subsequently sought from the participant upon regaining decision-making capacity or from a legal representative, as applicable.
    Title Hamburg Acute RenalKidney Injury Study (HARISHAKIS)
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07338669
Responsible party
Sponsor
First posted
Jan 14, 2026
Start date
Sep 16, 2025
Primary completion
Sep 2026 (estimated)
Completion
Sep 2030 (estimated)
Last update
Oct 1, 2026

Study contacts

Christian Schmidt-Lauber, MD
Contact
c.schmidt-lauber@uke.de
+49 (0) 40 7410 53908
Maja Lindenmeyer, PhD
Contact
m.lindenmeyer@uke.de
+49 (0) 40 7410 53908
Tobias B Huber, MD
principal investigator · Universitätsklinikum Hamburg-Eppendorf

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion